Compares urokinase and alteplase for acute ischemic stroke treatment
Compares safety and effectiveness of two clot-dissolving drugs in adults with stroke.
Plain-language title generated from the registry record
Registry title: Treatment of Acute Ischemic StroKe With Intravenous UroKinase Real-world Research: a Multicenter, Prospective Study
Key facts
- Where
- Anyang, Beiliu, Guidong, Jiamusi, Kaifeng, Lanzhou, Luoyang, Pingdingshan, Sanya, Tongliao, Wuzhou, Yulin, Zhanjiang, and Zhengzhou, ChinaSee the 16 sites
Where in China
- The People's Hospital of Anyang CityAnyang, ChinaNot yet recruiting
- Beiliu People's HospitalBeiliu, ChinaNot yet recruiting
- Guidong People's Hospital of Guangxi zhuang Autonomous RegionGuidong, ChinaNot yet recruiting
- The First Affiliated Hospital of Jiamusi UniversityJiamusi, ChinaNot yet recruiting
- Kaifeng Central HospitalKaifeng, ChinaNot yet recruiting
- The First People's Hospital of Lanzhou CityLanzhou, ChinaNot yet recruiting
- The Second People's Hospital of Mengjin DistrictLuoyang, ChinaNot yet recruiting
- Pingdingshan The second people's hospitalPingdingshan, ChinaNot yet recruiting
- Sanya People's HospitalSanya, ChinaNot yet recruiting
- Affiliated Hospital of Inner Mongolia Minzu UniversityTongliao, ChinaNot yet recruiting
- Tengxian People's HospitalWuzhou, ChinaNot yet recruiting
- Red Cross Hospital of Yulin CityYulin, ChinaNot yet recruiting
- The First people's hospital of YulinYulin, ChinaNot yet recruiting
- Affiliated Hospital of Guangdong Medical UniversityZhanjiang, ChinaNot yet recruiting
- Huiji District People's HospitalZhengzhou, ChinaNot yet recruiting
- The First Affiliated Hospital of Zhengzhou UniversityZhengzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The First Affiliated Hospital of Zhengzhou University
- Trial code
- NCT06194968
- Record updated
- 8 January 2024
- Original description
The purpose of this study is to to compare the safety and effectiveness of IV urokinase with IV alteplase in the treatment of AIS in patients up to 6 hours from symptom onset.Read full original descriptionShow less
Treatment of Acute Ischemic StroKe With Intravenous UroKinase Real-world Research: a Multicenter, Prospective Study (TASK-UK)
The purpose of this study is to to compare the safety and effectiveness of IV urokinase with IV alteplase in the treatment of AIS in patients up to 6 hours from symptom onset.
Inclusion: First-time occurrence or a history of stroke without significant neurological deficits (baseline mRS score ≤ 1); Eligible for treatment with intravenous administration of urokinase or alteplase as assessed by the investigators; Patient is willing to participate voluntarily and to sign a written patient informed consent. Informed consent will be obtained from each patient or the subject's legally authorized representative or relatives, or deferred where applicable; -.
Exclusion: Has an expected survival of less than 90 days due to concurrent malignant tumors or severe systemic diseases Incapable to comply with the protocol due to mental illness or cognitive disorder; Paticipants of any interventional drug or device clinical trials within 3 months prior to screening; Known history of drug (narcotics, controlled substances) abuse or addiction in the past year; Female of childbearing potential who is known to be pregnant and/or lactating or who has a positive pregnancy test on admission; Unsuitable for this study in the opinion of the investigators; -.